Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Shares Outstanding (Diluted Average) (2020 - 2025)

SAB Biotherapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $77.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 740.93% year-over-year to $77.9 million; the TTM value through Sep 2025 reached $77.9 million, up 740.93%, while the annual FY2024 figure was $9.3 million, 67.74% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $77.9 million in Q3 2025 per SABSW's latest filing, up from $9.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $77.9 million in Q3 2025 to a low of $4.4 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $20.5 million, with a median of $9.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 89.0% in 2023, then surged 740.93% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $27.3 million in 2021, then crashed by 84.08% to $4.4 million in 2022, then grew by 26.86% to $5.5 million in 2023, then surged by 67.74% to $9.3 million in 2024, then skyrocketed by 740.68% to $77.9 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Shares Outstanding (Diluted Average) are $77.9 million (Q3 2025), $9.3 million (Q2 2025), and $9.3 million (Q1 2025).